Eloise Dray


Former Research Fellow

Research Themes

Cancer and Blood Diseases


About me

Dr Eloïse Dray received her PhD from University Paris 11 in France, where she evidenced the first interaction between the breast cancer predisposition protein BRCA2 and the human meiotic recombinase DMC1. She then moved on to Patrick Sung laboratory at Yale University, where she became conversant with protein biochemistry. All along her postdoctoral training, she investigated the link between breast cancer (BRCA2, PALB2) and DNA repair pathways. There, she deciphered the function of several proteins that are now considered essential to DNA repair mechanisms in human.

Dr Dray started her first research group in 2013, and is pursuing breast cancer research with the support of the National Breast Cancer Foundation, the Princess Alexandra Foundation and the Cancer Council Queensland. Her team included Romain Tropée and Bárbara de la Peña Avalos (PhD students), Carina Walpole (Senior Research Assistant), Aaron McDonald (Honours student) and Veah Tapat (Administrator). 

Dr Dray has now moved to the United States and is a Research Assistant Professor at University of Texas Health Center at San Antonio




Selected publications

NUCKS1 is a novel RAD51AP1 paralog important for homologous recombination and genome stability. Parplys, A; zhao, W; Sharma, N; Groesser, T; Liang, F; Maranon, D; Leung, S; Grundt, K; Dray, E; Idate, R; Ostvold, A; Schild, D; Sung, P; Wiese, C.Nucleic Acid Research NAR-00920-D-2015.R2 (in press).

PRMT2 and RORγ expression are associated with breast cancer survival outcomes. Gyu Oh T, Bailey P, Dray E, Smith AG, Goode J, Eriksson N, Funder JW, Fuller PJ, Simpson ER, Tilley WD, Leedman PJ, Clarke CL, Grimmond S, Dowhan DH, Muscat GE. Mol Endocrinol. 2014 Jul;28(7):1166-85.

Tunable "nano-shearing": a physical mechanism to displace nonspecific cell adhesion during rare cell detection. Vaidyanathan R, Shiddiky MJ, Rauf S, Dray E, Tay Z, Trau M. Anal Chem. 2014 Feb 18;86(4):2042-9.

Targeting cancer with a lupus autoantibody.  Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM. Sci Transl Med. 2012 Oct 24;4(157):157ra142.

A variant of the breast cancer type 2 susceptibility protein (BRC) repeat is essential for the RECQL5 helicase to interact with RAD51 recombinase for genome stabilization. Islam MN, Paquet N, Fox D 3rd, Dray E, Zheng XF, Klein H, Sung P, Wang W. J Biol Chem. 2012 Jul 6;287(28):23808-18.

Mechanistic insights into RAD51-associated protein 1 (RAD51AP1) action in homologous DNA repair. Dunlop MH, Dray E, Zhao W, San Filippo J, Tsai MS, Leung SG, Schild D, Wiese C, Sung P. J Biol Chem. 2012 Apr 6;287(15):12343-7.

RAD51-associated protein 1 (RAD51AP1) interacts with the meiotic recombinase DMC1 through a conserved motif. Dunlop MH, Dray E, Zhao W, Tsai MS, Wiese C, Schild D, Sung P. J Biol Chem. 2011 Oct 28;286(43):37328-34.

Molecular basis for enhancement of the meiotic DMC1 recombinase by RAD51 associated protein 1 (RAD51AP1). Dray E, Dunlop MH, Kauppi L, San Filippo J, Wiese C, Tsai MS, Begovic S, Schild D, Jasin M, Keeney S, Sung P. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3560-5.

Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Dray E, Etchin J, Wiese C, Saro D, Williams GJ, Hammel M, Yu X, Galkin VE, Liu D, Tsai MS, Sy SM, Schild D, Egelman E, Chen J, Sung P. Nat Struct Mol Biol. 2010 Oct;17(10):1255-9.

Yeast Mph1 helicase dissociates Rad51-made D-loops: implications for crossover control in mitotic recombination. Prakash R, Satory D, Dray E, Papusha A, Scheller J, Kramer W, Krejci L, Klein H, Haber JE, Sung P, Ira G. Genes Dev. 2009 Jan 1;23(1):67-79.

Promotion of homologous recombination and genomic stability by RAD51AP1 via RAD51 recombinase enhancement. Wiese C, Dray E, Groesser T, San Filippo J, Shi I, Collins DW, Tsai MS, Williams GJ, Rydberg B, Sung P, Schild D. Mol Cell. 2007 Nov 9;28(3):482-90.


Extended publications: